On Monday, Divi Laboratories consolidated net profit, which has been increased by 78 per cent to Rs 895 crore in the fourth quarter on March 31, 2022. In the last quarter, the drugmaker has reported a net profit of Rs 502 crore, and revenue from operation rose to Rs 2 518 crores, against Rs 1 788 crore in the year-ago period, as per the company’s statement.

• Tata Power Inks MoU with Asian Development Bank for $4.25 Billion 
• Innovators Facade Shares Skyrocketed 11% on Securing Orders Worth Rs 110 Crore 
• Stocks in Focus: SJVN, Tata Power, Afcons Infrastructure, and Others
• Stocks Under F&O Ban: Adani Enterprises, Aarti Industries, Indraprastha Gas, and Others 
• RBI Defends Currency Moves to Protect Economy

For the year ended in March 2022, Divi Laboratories Ltd posted a consolidated net profit of Rs 2,960 crore against Rs 1,984 crore in FY21.

Revenue from operations rose to Rs 8,960 crore compared to Rs 6,969 crore in 2020-21.
The company said its board had recommended a dividend of Rs 30 per share of the face value of Rs 2 (1,500 per cent) for 2021-22, subject to members’ approval at the ensuing annual general meeting.

Shares of the company were trading 6.37 per cent down at Rs 4,032.35 apiece on the Bombay Stock Exchange (BSE).